Candel Therapeutics, Inc.
CADLHealthcareNASDAQBiotechnology
Scan Results
Daily timeframeCandel Therapeutics, Inc., a clinical stage biopharmaceutical company, develops immunotherapies for cancer patients. Valued at $745.9M, CADL is a small-cap name in its sector. It develops CAN-2409, which is in Phase 2a clinical trials for the treatment of prostate cancer; and Phase 2a clinical trials for the treatment of non-small cell lung cancer (NSCLC).
Market Cap
$745.9M
Beta
-0.51
P/E (TTM)
—
P/E (Fwd)
-16.83
EPS (TTM)
$-1.08
EPS (Fwd)
$-0.60
ROE
-51.2%
ROA
-23.6%
Cash
$194.8M
Total Debt
$49.3M
Free CF
-$37.9M
52W Change
51.0%
Annual Financials
Cash vs Debt
The balance sheet looks solid with $194.8M in cash comfortably exceeding the $49.3M debt load. A net cash position generally provides financial flexibility during uncertain economic periods. Free cash flow is running at -$37.9M, which bears watching. Negative free cash flow can be acceptable during heavy investment periods but needs to improve over time. ROE of -51.2% points to negative capital efficiency, indicating how much profit the company produces per dollar of shareholder equity. Revenue has pulled back from $125K (2022) to $0 (2025), a 100% decline worth watching.
CADL's low beta indicates it tends to be less volatile than the broader market, which may suit investors seeking more stable price behavior. With cash comfortably exceeding debt, CADL has financial flexibility that may help navigate uncertain periods. The company is burning cash at the operating level, which is not unusual for growth-phase companies but adds risk if it persists. It is important to consider these factors alongside broader market conditions and individual financial goals when reviewing CADL.